Abstract
Background: As new biomolecular targets for Alzheimer’s disease (AD) emerge, there is a tendency to regard these as mutually exclusive and in competition, culminating in declarations that since the “amyloid hypothesis is dead” it needs to be replaced by completely different theories. However, given the well-described role of misfolding peptides, particularly β-amyloid (Aβ), in the pathogenesis of AD, the need for a broad-based conceptualization of AD, coalescing different theories into a single harmonized explanation emerges as a viable alternative. Incorporating protein aggregation mechanisms of AD into a more widely-encompassing immunopathic model of AD could accomplish such a goal-a goal which could be achieved by repositioning the role of Aβ as an immunopeptide.
Conclusion: This review presents the concept that Aβ is an immunopeptide and that AD is an autoimmune disease in which Aβ is a key molecular player. Being a peptide with the capacity to alter immune function, Aβ is an immunopeptide; having both antimicrobial and immunomodulatory activities, Aβ is a host defense peptide; having most of the defining properties of cytokines, Aβ satisfies the broad definition of cytokine-the prototypic immunopeptide subtype. In addition to these immunoactivities, Aβ is also directly and independently cytotoxic to neurons by both necrotic and apoptotic mechanisms. Therefore, following brain exposure to immune-instigating stimuli, the innate immune system is activated, leading to the release of Aβ as an immunopeptide (functioning as a host defense peptide or cytokine), which subsequently inflicts a misdirected attack upon the host neurons-an autoimmune event.
Keywords: Alzheimer's disease, dementia, neuroinflammation, autoimmune, cytokine, antimicrobial peptide, amyloid-beta, immunopeptide.
Current Alzheimer Research
Title:β-Amyloid is an Immunopeptide and Alzheimer’s is an Autoimmune Disease
Volume: 18 Issue: 11
Author(s): Donald F. Weaver *
Affiliation:
- Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON,Canada
Keywords: Alzheimer's disease, dementia, neuroinflammation, autoimmune, cytokine, antimicrobial peptide, amyloid-beta, immunopeptide.
Abstract:
Background: As new biomolecular targets for Alzheimer’s disease (AD) emerge, there is a tendency to regard these as mutually exclusive and in competition, culminating in declarations that since the “amyloid hypothesis is dead” it needs to be replaced by completely different theories. However, given the well-described role of misfolding peptides, particularly β-amyloid (Aβ), in the pathogenesis of AD, the need for a broad-based conceptualization of AD, coalescing different theories into a single harmonized explanation emerges as a viable alternative. Incorporating protein aggregation mechanisms of AD into a more widely-encompassing immunopathic model of AD could accomplish such a goal-a goal which could be achieved by repositioning the role of Aβ as an immunopeptide.
Conclusion: This review presents the concept that Aβ is an immunopeptide and that AD is an autoimmune disease in which Aβ is a key molecular player. Being a peptide with the capacity to alter immune function, Aβ is an immunopeptide; having both antimicrobial and immunomodulatory activities, Aβ is a host defense peptide; having most of the defining properties of cytokines, Aβ satisfies the broad definition of cytokine-the prototypic immunopeptide subtype. In addition to these immunoactivities, Aβ is also directly and independently cytotoxic to neurons by both necrotic and apoptotic mechanisms. Therefore, following brain exposure to immune-instigating stimuli, the innate immune system is activated, leading to the release of Aβ as an immunopeptide (functioning as a host defense peptide or cytokine), which subsequently inflicts a misdirected attack upon the host neurons-an autoimmune event.
Export Options
About this article
Cite this article as:
Weaver F. Donald *, β-Amyloid is an Immunopeptide and Alzheimer’s is an Autoimmune Disease, Current Alzheimer Research 2021; 18 (11) . https://dx.doi.org/10.2174/1567205018666211202141650
DOI https://dx.doi.org/10.2174/1567205018666211202141650 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Recombinant Human Insulin-Like Growth Factor-1: A New Cardiovascular Disease Treatment Option?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Alzheimer Pandemic: Is Paracetamol to Blame?
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Apigenin and Breast Cancers: From Chemistry to Medicine
Anti-Cancer Agents in Medicinal Chemistry Differential Expression of TOM34, AL1A1, PADI2 and KLRBA in NNK Induced Lung Cancer in Wistar Rats and their Implications
Current Cancer Drug Targets Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Antiproliferative and Antioxidant Potential of Leaf and Leaf Derived Callus Extracts of Aerva lanata (L.) Juss. Ex Schult. Against Human Breast Cancer (MCF-7) Cell Lines
The Natural Products Journal Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and their Treatment Implications
Current Neuropharmacology How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The “LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD
Current Alzheimer Research Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Patent Selections:
Recent Patents on Biomarkers Patent Selections
Recent Patents on Regenerative Medicine Unique Medicinal Properties of Withania somnifera: Phytochemical Constituents and Protein Component
Current Pharmaceutical Design Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets